Schneider et al. showed that the FLT3-ITD mRNA level has a high prognostic impact in NPM1-mutated AML-NK, and that it contributes to relapse risk stratification and might help to guide postremission therapy in NPM1- mutated AML [29]. The gene discussed is NPM1; the disease is acute myeloid leukemia.